Natalizumab treatment alters the expression of T-cell trafficking marker LFA-1 α-chain (CD11a) in MS patients.

Details

Serval ID
serval:BIB_75F2F83A31AE
Type
Article: article from journal or magazin.
Collection
Publications
Institution
Title
Natalizumab treatment alters the expression of T-cell trafficking marker LFA-1 α-chain (CD11a) in MS patients.
Journal
Multiple sclerosis (Houndmills, Basingstoke, England)
Author(s)
Jilek S., Mathias A., Canales M., Lysandropoulos A., Pantaleo G., Schluep M., Du Pasquier R.A.
ISSN
1477-0970 (Electronic)
ISSN-L
1352-4585
Publication state
Published
Issued date
06/2014
Peer-reviewed
Oui
Volume
20
Number
7
Pages
837-842
Language
english
Notes
Publication types: Journal Article
Publication Status: ppublish
Abstract
To determine the long-term effect of natalizumab (NTZ) treatment on the expression of integrins and chemokine receptors involved in the migration of T cells towards the central nervous system (CNS).
We drew the blood of 23 patients just before starting NTZ therapy and every 12 months thereafter, for up to 48 months of treatment. We assessed the ex-vivo expression of phenotype markers (CCR7 and CD45RA), CNS-addressing integrins (CD11a, CD49d and CD29) and chemokine receptors (CXCR3 and CCR6) in CD4+ or CD8+ T-cell subsets by flow cytometry.
As compared to the pre-NTZ values, there was a marked increase in central memory (CCR7+/CD45RA-) CD4+ T cells and in effector memory (CCR7-/CD45RA-) CD8+ T cells at 12 and 24 months. In addition to an expected downregulation of both VLA-4 subunits (CD49d/CD29), we also found decreased T-cell expression of CXCR3 at 12 months, and of CD11a (LFA-1 αL subunit) at 12 months, but mostly at 24 months of NTZ treatment.
Our data show a nadir of CD11a expression at 2 years of NTZ treatment, at the peak of incidence of progressive multifocal leukoencephalopathy (PML), indirectly suggesting that a lack of these molecules may play a role in the onset of PML in NTZ-treated patients.

Keywords
Adverse effects, CD11a, CXCR3, LFA-1, T cell, VLA-4, cellular immunity, integrins, longitudinal study, natalizumab, progressive multifocal encephalopathy
Pubmed
Web of science
Create date
27/07/2014 15:17
Last modification date
20/08/2019 14:33
Usage data